Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring - Archive ouverte HAL Access content directly
Journal Articles Cancers Year : 2021

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring

(1, 2) , (2) , (3, 2) , (3, 2) , (2) , (2) , (2) , (2) , (3, 2) , (3, 2)
1
2
3

Abstract

Non-small cell lung cancer (NSCLC) is the most common cancer in the world. Activating epidermal growth factor receptor (EGFR) gene mutations are a positive predictive factor for EGFR tyrosine kinase inhibitors (TKIs). For common EGFR mutations (Del19, L858R), the standard first-line treatment is actually third-generation TKI, osimertinib. In the case of first-line treatment by first (erlotinib, gefitinib)- or second-generation (afatinib) TKIs, osimertinib is approved in second-line treatment for patients with T790M EGFR mutation. Despite the excellent disease control results with EGFR TKIs, acquired resistance inevitably occurs and remains a biological challenge. This leads to the discovery of novel biomarkers and possible drug targets, which vary among the generation/line of EGFR TKIs. Besides EGFR second/third mutations, alternative mechanisms could be involved, such as gene amplification or gene fusion, which could be detected by different molecular techniques on different types of biological samples. Histological transformation is another mechanism of resistance with some biological predictive factors that needs tumor biopsy. The place of liquid biopsy also depends on the generation/line of EGFR TKIs and should be a good candidate for molecular monitoring. This article is based on the literature and proposes actual and future directions in clinical and translational research.
Fichier principal
Vignette du fichier
cancers-13-04926-v2.pdf (3.36 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03881957 , version 1 (05-12-2022)

Identifiers

Cite

Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, et al.. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers, 2021, 13 (19), pp.4926. ⟨10.3390/cancers13194926⟩. ⟨hal-03881957⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More